[HTML][HTML] A review on the effects of current chemotherapy drugs and natural agents in treating non–small cell lung cancer
CY Huang, DT Ju, CF Chang, PM Reddy… - Biomedicine, 2017 - ncbi.nlm.nih.gov
Lung cancer is the leading cause of cancer deaths worldwide, and this makes it an attractive
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …
disease to review and possibly improve therapeutic treatment options. Surgery, radiation …
Advances in studies of tyrosine kinase inhibitors and their acquired resistance
Q Jiao, L Bi, Y Ren, S Song, Q Wang, Y Wang - Molecular cancer, 2018 - Springer
Protein tyrosine kinase (PTK) is one of the major signaling enzymes in the process of cell
signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues …
signal transduction, which catalyzes the transfer of ATP-γ-phosphate to the tyrosine residues …
[HTML][HTML] Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer
Y Lei, W Guo, B Chen, L Chen… - Oncology …, 2018 - spandidos-publications.com
Currently, resistance to tyrosine kinase inhibitors, such as gefitinib, has become one major
obstacle for improving the clinical outcome of patients with metastatic and advanced‑stage …
obstacle for improving the clinical outcome of patients with metastatic and advanced‑stage …
Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial
Background Tubal ectopic pregnancies can cause substantial morbidity or even death.
Current treatment is with methotrexate or surgery. Methotrexate treatment fails in …
Current treatment is with methotrexate or surgery. Methotrexate treatment fails in …
Antisense oligonucleotides targeting angiogenic factors as potential cancer therapeutics
Cancer is one of the leading causes of death worldwide, and conventional cancer therapies
such as surgery, chemotherapy, and radiotherapy do not address the underlying molecular …
such as surgery, chemotherapy, and radiotherapy do not address the underlying molecular …
RETRACTED ARTICLE: The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC
X Li, X Zhang, C Yang, S Cui, Q Shen, S Xu - Cell Cycle, 2018 - Taylor & Francis
Statement of Retraction We, the Editors and Publisher of the journal Cell Cycle, have
retracted the following article: Xuehao Li, Xin Zhang, Chunlu Yang, Sui Cui, Qiming Shen …
retracted the following article: Xuehao Li, Xin Zhang, Chunlu Yang, Sui Cui, Qiming Shen …
Lung cancer survival among never smokers
A Casal-Mourino, L Valdes, JM Barros-Dios… - Cancer letters, 2019 - Elsevier
Lung cancer incidence among never smokers has increased in recent decades with 10–
30% of all lung cancers occurring in never smokers, where exposure to residential radon is …
30% of all lung cancers occurring in never smokers, where exposure to residential radon is …
MiR-450a-5p strengthens the drug sensitivity of gefitinib in glioma chemotherapy via regulating autophagy by targeting EGFR
Y Liu, L Yang, F Liao, W Wang, ZF Wang - Oncogene, 2020 - nature.com
Glioma reported to be refractory to EGFR tyrosine kinase inhibitor is the most common
malignant tumor in central nervous system. Our research showed the low expression of miR …
malignant tumor in central nervous system. Our research showed the low expression of miR …
[HTML][HTML] Affilin-based retargeting of adenoviral vectors to the epidermal growth factor receptor
F Wienen, R Nilson, E Allmendinger, D Graumann… - Biomaterials …, 2023 - Elsevier
Introduction Treatment of head and neck squamous cell carcinomas (HNSCC) by oncolytic
adenoviral vectors holds promise as an efficient anti-cancer therapy. The epidermal growth …
adenoviral vectors holds promise as an efficient anti-cancer therapy. The epidermal growth …
Craft of co-encapsulation in nanomedicine: a struggle to achieve synergy through reciprocity
S Bhattacharjee - ACS Pharmacology & Translational Science, 2022 - ACS Publications
Achieving synergism, often by combination therapy via codelivery of chemotherapeutic
agents, remains the mainstay of treating multidrug-resistance cases in cancer and microbial …
agents, remains the mainstay of treating multidrug-resistance cases in cancer and microbial …